The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | How will liquid biopsies improve early detection of lung cancer?
Umberto Malapelle, PhD, University of Naples Federico II, Naples, Italy, evaluates the emerging role of liquid biopsies in detecting lung cancer and possible limitations in its clinical implementation. While liquid biopsies can improve and expedite early detection, especially with newer techniques such as next-generation sequencing (NGS), specificity remains an issue. In addition to circulating tumor DNA (ctDNA), other molecular markers such as methylation and circulating tumor cells (CTCs) will help increase the efficacy of liquid biopsies. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
